Abstract

Prion diseases have been linked to impaired copper homeostasis and copper induced-oxidative damage to the brain. Divalent metal ions, such as Cu2+ and Zn2+, bind to cellular prion protein (PrPC) at octapeptide repeat (OR) and non-OR sites within the N-terminal half of the protein but information on the impact of such binding on conversion to the misfolded isoform often derives from studies using either OR and non-OR peptides or bacterially-expressed recombinant PrP. Here we created new transgenic mouse lines expressing PrP with disrupted copper binding sites within all four histidine-containing OR's (sites 1–4, H60G, H68G, H76G, H84G, "TetraH>G" allele) or at site 5 (composed of residues His-95 and His-110; "H95G" allele) and monitored the formation of misfolded PrP in vivo. Novel transgenic mice expressing PrP(TetraH>G) at levels comparable to wild-type (wt) controls were susceptible to mouse-adapted scrapie strain RML but showed significantly prolonged incubation times. In contrast, amino acid replacement at residue 95 accelerated disease progression in corresponding PrP(H95G) mice. Neuropathological lesions in terminally ill transgenic mice were similar to scrapie-infected wt controls, but less severe. The pattern of PrPSc deposition, however, was not synaptic as seen in wt animals, but instead dense globular plaque-like accumulations of PrPSc in TgPrP(TetraH>G) mice and diffuse PrPSc deposition in (TgPrP(H95G) mice), were observed throughout all brain sections. We conclude that OR and site 5 histidine substitutions have divergent phenotypic impacts and that cis interactions between the OR region and the site 5 region modulate pathogenic outcomes by affecting the PrP globular domain.

Highlights

  • Prion diseases such as Creutzfeldt-Jakob disease and bovine spongiform encephalopathy are progressive neurodegenerative disorders that are caused by the structural conversion and aggregation of the normal cellular prion protein (PrPC) to a misfolded, partially protease-resistant isoform (PrPSc) [1]

  • Constructs were microinjected into fertilized oocytes on a PrP knockout genetic background (Prnp0/0, 129/Sv-C57/ Bl6), with offspring of four founder lines expanded for further study

  • Deglycosylation revealed that PrPC encoded by the PrP(TetraH>G) and PrP(H95G) transgenes was represented by a C1 endoproteolytic fragment as well as full-length protein

Read more

Summary

Introduction

Prion diseases such as Creutzfeldt-Jakob disease and bovine spongiform encephalopathy are progressive neurodegenerative disorders that are caused by the structural conversion and aggregation of the normal cellular prion protein (PrPC) to a misfolded, partially protease-resistant isoform (PrPSc) [1]. The mechanistic details of replication and disease pathogenesis are not understood in detail, but appear to involve direct interaction between PrPC and PrPSc [3, 4]. In this context, the intrinsically disordered N-terminal domain of PrPC is suggested to play a role in modulating the physiological function of PrPC as well as altering pathological outcomes in prion diseases [1, 5,6,7]. At physiological pH, the N-terminal domain can selectively bind up to six Cu2+ ions with the first 2 molar equivalents of Cu2+ binding to the amyloidogenic region of human PrPC containing His-96 and His-111 (“site 5”), and to the four binding sites provided by the OR region [8, 9]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call